Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 12.86 as of 2026-10-06T16:35:26.441Z.
Consensus retrieved: 2026-10-06T08:26:30.288Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:35:26.441Z.
Quote observation: 2026-10-06T16:35:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cc8bc0f3c1d6793fd8eee0ad66748b6583cc3e3afc130d7083cfc2a78972af23
Forward PE Ratio (12.86) = Dated Quote Price ($10.25) / Consensus Forward EPS ($0.80)
FORWARD PE RATIO
12.86
SECTOR MEDIAN · HEALTHCARE
19.63
median of 178 covered companies
CURRENT VS SECTOR MEDIAN
-34.47%
vs the sector median at left
ADMA Biologics, Inc.
Market Cap
$2.37B
Forward PE Ratio
12.86
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ADMA Biologics, Inc. (ADMA) | $2.37B | 12.86 |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.36B | N/A |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.40B | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.41B | 82.83 |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.42B | N/A |
| Disc Medicine, Inc. (IRON)vs › | $2.43B | N/A |
| Liquidia Corporation (LQDA)vs › | $2.32B | 10.50 |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.29B | 10.03 |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.28B | N/A |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.58B | N/A |
Trailing P/E
14.6
reported TTM EPS
Forward P/E
12.9
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.80 implies +14.3% EPS growth vs the reported trailing $0.70.
At the dated quote price of $10.25, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.80 | $0.76 – $0.84 | 3 | 12.9x |
| 2027-12-31 | $0.94 | $0.80 – $1.14 | 3 | 10.9x |
| 2028-12-31 | $1.20 | $1.03 – $1.33 | 3 | 8.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
